Objective To determine differences in TNF-α, IL-1β, IL-10, sICAM-1 concentrations, leg hypoxia and whole blood viscosity (WBV) at shear rates of 46 sec-1 and 230 sec-1 in persons with homozygous S sickle cell disease (SCD) with and without chronic leg ulceration and in AA genotype controls. Design & Methods: fifty-five age-matched participants were recruited into the study: 31 SS subjects without leg ulcers (SSn), 24 SS subjects with leg ulcers (SSu) and 18 AA controls. Haematological indices were measured using an AC.Tron Coulter Counter. Quantification of inflammatory, anti-inflammatory and adhesion molecules was performed by ELISA. Measurement of whole blood viscosity was done using a Wells Brookfield cone-plate viscometer. Quantification of microvascular tissue oxygenation was done by Visible Lightguide spectrophotometry. Results TNF-α and whole blood viscosity at 46 sec-1 and 230 sec-1 (1.75, 2.02 vs. 0.83, 1.26, p<0.05) were significantly greater in sickle cell disease subjects than in controls. There were no differences in plasma concentration of sICAM-1, IL-1β and IL-10 between SCD subjects and controls. IL-1β (median, IQR: 0.96, 1.7 vs. 0, 0.87; p<0.01) and sICAM-1 (226.5, 156.48 vs. 107.63, 121.5, p<0.005) were significantly greater in SSu group compared with SSn. However there were no differences in TNF-α (2, 3.98 vs. 0, 2.66) and IL-10 (13.34, 5.95 vs. 11.92, 2.99) concentrations between SSu and SSn. WBV in the SSu group at 46 sec-1 and at 230 Sec 1 were 1.9 (95%CI; 1.2, 3.1) and 2.3 (1.2, 4.4) times greater than in the SSn group. There were no differences in the degree of tissue hypoxia as determined by lightguide spectrophotometry. Conclusion Inflammatory, adhesion markers and WBV may be associated with leg ulceration in sickle cell disease by way of inflammation-mediated vasoocclusion/vasoconstriction. Impaired skin oxygenation does not appear to be associated with chronic ulcers in these subjects with sickle cell disease.
References
[1]
Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R et al. (1989) Leg ulcers in patients with sickle cell disease. Blood 74: 1403-1408. PubMed: 2475188.
[2]
Serjeant RG, Serjeant EB (2001) Sickle cell disease. 56. Oxford University Press & 59 p.
[3]
Serjeant GR (1974) Leg ulceration in sickle cell anemia. Arch Intern Med 133: 690-694. doi:10.1001/archinte.1974.00320160184017. PubMed: 4818436.
[4]
Cumming V, King L, Fraser R, Serjeant G, Reid M (2008) Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. Br J Haematol 142: 119-125. doi:10.1111/j.1365-2141.2008.07115.x. PubMed: 18477043.
[5]
Mohan J, Marshall JM, Reid HL, Thomas PW, Hambleton I et al. (1998) Peripheral vascular response to mild indirect cooling in patients with homozygous sickle cell (SS) disease and the frequency of painful crisis. Clin Sci (Lond) 94: 111-120. PubMed: 9536918.
[6]
Mohan JS, Marshall JM, Reid HL, Thomas PW, Serjeant GR (1997) Postural vasoconstriction and leg ulceration in homozygous sickle cell disease. Clin Sci (Lond) 92: 153-158. PubMed: 9059316.
[7]
Fitzhugh CD, Lauder N, Jonassaint JC, Telen MJ, Zhao X et al.. (2010) Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 85: 36-40. PubMed: 20029950.
[8]
Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J et al. (2008) Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 111: 5721-5726. doi:10.1182/blood-2007-02-074849. PubMed: 18187665.
[9]
Kato GJ, Gladwin MT, Steinberg MH (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 21: 37-47. doi:10.1016/j.blre.2006.07.001. PubMed: 17084951.
[10]
Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96: 2451-2459. PubMed: 11001897.
[11]
de Montalembert M, Aggoun Y, Niakate A, Szezepanski I, Bonnet D (2007) Endothelial-dependent vasodilation is impaired in children with sickle cell disease. Haematologica 92: 1709-1710. doi:10.3324/haematol.11253. PubMed: 18055999.
[12]
Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W et al. (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136: 1680-1687. PubMed: 3485132.
[13]
Shiu YT, Udden MM, McIntire LV (2000) Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 95: 3232-3241. PubMed: 10807794.
[14]
Swerlick RA, Lawley TJ (1993) Role of microvascular endothelial cells in inflammation. J Invest Dermatol 100: 111S-115S. doi:10.1038/jid.1993.33. PubMed: 8423379.
[15]
Bijl M (2003) Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med 61: 273-277. PubMed: 14692439.
[16]
Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH (1980) Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 302: 992-995. doi:10.1056/NEJM198005013021803. PubMed: 7366623.
[17]
Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV (1993) Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 82: 3548-3555. PubMed: 7505118.
[18]
Rajbhandari SM, Harris ND, Tesfaye S, Ward JD (1999) Early identification of diabetic foot ulcers that may require intervention using the micro lightguide spectrophotometer. Diabetes Care 22: 1292-1295. doi:10.2337/diacare.22.8.1292. PubMed: 10480773.
[19]
Ratliff DA, Clyne CA, Chant AD, Webster JH (1984) Prediction of amputation wound healing: the role of transcutaneous pO2 assessment. Br J Surg 71: 219-222. doi:10.1002/bjs.1800710320. PubMed: 6697129.
[20]
Mohan JS, Vigilance JE, Marshall JM, Hambleton IR, Reid HL et al. (2000) Abnormal venous function in patients with homozygous sickle cell (SS) disease and chronic leg ulcers. Clin Sci (Lond) 98: 667-672. doi:10.1042/CS20000004. PubMed: 10814603.
[21]
Gniadecka M, Gniadecki R, Serup J, S？ndergaard J (1994) Microvascular reactions to postural changes in patients with sickle cell anaemia. Acta Derm Venereol 74: 191-193. PubMed: 7915459.
[22]
Harrison DK, Hawthorn IE (2005) Amputation level viability in critical limb ischaemia: setting new standards. Adv Exp Med Biol 566: 325-331. doi:10.1007/0-387-26206-7_43. PubMed: 16594169.
[23]
Harrison DK, McCollum PT, Newton DJ, Hickman P, Jain AS (1995) Amputation level assessment using lightguide spectrophotometry. Prosthet Orthot Int 19: 139-147. PubMed: 8927524.
[24]
Harrison DK, Newton DJ, McCollum PT, Jain AS (1996) Lightguide spectrophotometry for the assessment of skin healing viability in critical limb ischaemia. Adv Exp Med Biol 388: 45-51. doi:10.1007/978-1-4613-0333-6_5. PubMed: 8798793.
[25]
Quimby KR, Greenidge AR, Hennis AJ, Harrison DK, Landis RC (2010) Tumor necrosis factor receptor-associated periodic syndrome P46L and bilateral amputation in diabetes. Rheumatology (Oxf) 49: 2454-2455. doi:10.1093/rheumatology/keq227. PubMed: 20634234.
[26]
Bowers AS, Pepple DJ, Reid HL (2008) Oxygen delivery index in subjects with normal haemoglobin (HbAA), sickle cell trait (HbAS) and homozygous sickle cell disease (HbSS). Clin Hemorheol Microcirc 40: 303-309. PubMed: 19126993.
[27]
Bowers AS, Pepple DJ, Reid HL (2009) Oxygen delivery index in homozygous sickle cell disease: steady and crisis states. Br J Biomed Sci 66: 148-149. PubMed: 19839226.
[28]
Kameneva MV, Watach MJ, Borovetz HS (1999) Gender difference in rheologic properties of blood and risk of cardiovascular diseases. Clin Hemorheol Microcirc 21: 357-363. PubMed: 10711771.
[29]
Alexy T, Pais E, Armstrong JK, Meiselman HJ, Johnson CS et al. (2006) Rheologic behavior of sickle and normal red blood cell mixtures in sickle plasma: implications for transfusion therapy. Transfusion 46: 912-918. doi:10.1111/j.1537-2995.2006.00823.x. PubMed: 16734807.
[30]
Baskurt OK, Boynard M, Cokelet GC, Connes P, Cooke BM et al. (2009) New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc 42: 75-97. PubMed: 19433882.
[31]
Tripette J, Alexy T, Hardy-Dessources MD, Mougenel D, Beltan E et al. (2009) Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease. Haematologica 94: 1060-1065. doi:10.3324/haematol.2008.005371. PubMed: 19644138.
[32]
Singh DB, Stansby G, Harrison DK (2008) Assessment of oxygenation and perfusion in the tongue and oral mucosa by visible spectrophotometry and laser Doppler flowmetry in healthy subjects. Adv Exp Med Biol 614: 227-233. doi:10.1007/978-0-387-74911-2_26. PubMed: 18290333.
[33]
Francis RB Jr., Haywood LJ (1992) Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 84: 611-615. PubMed: 1629925.
[34]
Croizat H (1994) Circulating cytokines in sickle cell patients during steady state. Br J Haematol 87: 592-597. doi:10.1111/j.1365-2141.1994.tb08318.x. PubMed: 7527647.
[35]
Kuvibidila S, Gardner R, Ode D, Yu L, Lane G et al. (1997) Tumor necrosis factor alpha in children with sickle cell disease in stable condition. J Natl Med Assoc 89: 609-615. PubMed: 9302858.
[36]
Malavé I, Perdomo Y, Escalona E, Rodriguez E, Anchustegui M et al. (1993) Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol 90: 172-176. doi:10.1159/000204452. PubMed: 8140855.
[37]
Thomas AN, Pattison C, Serjeant GR (1982) Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 285: 633-635. doi:10.1136/bmj.285.6342.633. PubMed: 6819042.
[38]
Powars D, Chan LS, Schroeder WA (1990) The variable expression of sickle cell disease is genetically determined. Semin Hematol 27: 360-376. PubMed: 2255920.
[39]
Thomson AP, Dick M (1988) Endotoxinaemia in sickle cell disease. Clin Lab Haematol 10: 397-401. PubMed: 3074892.
[40]
Musa BO, Onyemelukwe GC, Hambolu JO, Mamman AI, Isa AH (2010) Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol 17: 602-608. doi:10.1128/CVI.00145-09. PubMed: 20130127.
[41]
Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM et al. (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94: 119-126. doi:10.1161/01.RES.0000109414.78907.F9. PubMed: 14656926.
[42]
Herzyk DJ, Allen JN, Marsh CB, Wewers MD (1992) Macrophage and monocyte IL-1 beta regulation differs at multiple sites. Messenger RNA expression, translation, and post-translational processing. J Immunol 149: 3052-3058. PubMed: 1401931.
[43]
Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J et al. (2001) Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 21: 6461-6469. doi:10.1128/MCB.21.9.6461-6469.2001. PubMed: 11533235.
[44]
Ribeiro SP, Villar J, Downey GP, Edelson JD, Slutsky AS (1996) Effects of the stress response in septic rats and LPS-stimulated alveolar macrophages: evidence for TNF-alpha posttranslational regulation. Am J Respir Crit Care Med 154: 1843-1850. doi:10.1164/ajrccm.154.6.8970379. PubMed: 8970379.
[45]
Volpe F, Clatworthy J, Kaptein A, Maschera B, Griffin AM et al. (1997) The IL1 receptor accessory protein is responsible for the recruitment of the interleukin-1 receptor associated kinase to the IL1/IL1 receptor I complex. FEBS Lett 419: 41-44. doi:10.1016/S0014-5793(97)01426-9. PubMed: 9426216.
[46]
Movat HZ (1987) Tumor necrosis factor and interleukin-1: role in acute inflammation and microvascular injury. J Lab Clin Med 110: 668-681. PubMed: 3316455.
[47]
Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML et al. (1989) Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74: 165-172. PubMed: 2752108.
[48]
Upchurch GR Jr., Keagy BA, Johnson G Jr. (1997) An acute phase reaction in diabetic patients with foot ulcers. Cardiovasc Surg 5: 32-36. doi:10.1016/S0967-2109(97)89848-1. PubMed: 9158120.
[49]
Tsushima N, Matsuo H, Hayashi T, Homma S (1996) The clinical features and treatment of arteriosclerosis obliterans with diabetes. Diabetes 45 Suppl 3: S101-S104. doi:10.2337/diabetes.45.1.101. PubMed: 8674871.
[50]
Bogar L, Juricskay I, Kesmarky G, Kenyeres P, Toth K (2005) Erythrocyte transport efficacy of human blood: a rheological point of view. Eur J Clin Invest 35: 687-690. doi:10.1111/j.1365-2362.2005.01562.x. PubMed: 16269018.
[51]
Bogar L, Juricskay I, Kesmarky G, Feher G, Kenyeres P et al. (2006) Gender differences in hemorheological parameters of coronary artery disease patients. Clin Hemorheol Microcirc 35: 99-103. PubMed: 16899912.
[52]
Sohn MW, Budiman-Mak E, Lee TA, Oh E, Stuck RM (2011) Significant J-shaped association between body mass index (BMI) and diabetic foot ulcers. Diabetes/Metab Res Rev 27: 402-409. doi:10.1002/dmrr.1193. PubMed: 21360633.
[53]
Abouaesha F, van Schie CH, Griffths GD, Young RJ, Boulton AJ (2001) Plantar tissue thickness is related to peak plantar pressure in the high-risk diabetic foot. Diabetes Care 24: 1270-1274. doi:10.2337/diacare.24.7.1270. PubMed: 11423514.
[54]
Asleh R, Levy AP (2005) In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 1: 19-28. doi:10.2147/vhrm.1.1.19.58930. PubMed: 17319095.
[55]
Morel C (2001) [Retinal involvement in hemoglobinopathy]. J Fr Ophtalmol 24: 987-992. PubMed: 11912846.
[56]
Alleyne SI, Wint E, Serjeant GR (1977) Social effects of leg ulceration in sickle cell anemia. South Med J 70: 213-214. doi:10.1097/00007611-197702000-00033. PubMed: 841405.
[57]
Smith PC (2006) The causes of skin damage and leg ulceration in chronic venous disease. Int J Low Extrem Wounds 5: 160-168. doi:10.1177/1534734606292429. PubMed: 16928672.
[58]
Kato GJ, McGowan V, Machado RF, Little JA, Taylor Jt et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107: 2279-2285. doi:10.1182/blood-2005-06-2373. PubMed: 16291595.
